In a randomized controlled clinical trial, investigators will compare the effects on
[18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from
two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate
responders (MTX-IRs). Two common RA treatments will be compared: triple therapy
(sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF)
inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and
hydroxychloroquine for subjects who were taking this at screening).